Significance of chromogranin A and synaptophysin in medullary thyroid carcinoma.
Adolescent
Adult
Aged
Calcitonin
/ blood
Carcinoma, Neuroendocrine
/ metabolism
Chromogranin A
/ biosynthesis
Female
Humans
Immunohistochemistry
/ methods
Male
Middle Aged
Multiple Endocrine Neoplasia
/ metabolism
Synaptophysin
/ biosynthesis
Thyroid Gland
/ metabolism
Thyroid Neoplasms
/ metabolism
Young Adult
Journal
Bosnian journal of basic medical sciences
ISSN: 1840-4812
Titre abrégé: Bosn J Basic Med Sci
Pays: Bosnia and Herzegovina
ID NLM: 101200947
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
15
12
2020
accepted:
24
12
2020
pubmed:
25
1
2021
medline:
20
1
2022
entrez:
24
1
2021
Statut:
epublish
Résumé
Medullary thyroid carcinoma (MTC) is a relatively rare thyroid carcinoma of C-cell deviation and produces and secrete calcitonin (CT) and chromogranin A (CgA) into the blood. Thus, both CT and CgA are immunohistochemical and serum markers for MTCs. MTC occurs in both sporadic and inheritable cases and the hallmark of inheritable cases in multiple endocrine neoplasm 2 (NEN2) is MTC. MEN2 cases represent 30% of MTCs through germline RET protooncogene mutation and occur in younger ages involving bilateral thyroid lobes. Sporadic cases are 70% of cases of solitary tumor and occur in older ages. CgA and synaptophysin (SPY) are the two, most widely used and reliable immunohistochemical markers for neuroendocrine tumors including MTCs. This study aimed to detect different immunohistochemical staining patterns for CgA and SPY between non-symptomatic small, microscopic lesions and invading larger aggressive tumors in both MEA2 cases and sporadic cases. There was different CgA and SPY immunostaining in MEA2 cases where small tumors (≤ 0.3 cm) were lesser immunostained for CgA and SPY, despite strong staining for CT, compared to the larger (≥ 0.5cm) tumors, stronger immunostained for CgA. There was also different CgA and SPY immunohistochemical staining in sporadic cases between small lesion (≤ 0.5 cm) and larger tumors (≥ 1.0cm). One small sporadic tumor (0.5 x 0.3 cm) was strongly and weakly, patchy (about 10% of tumor tissue) stained for CgA and SPY, respectively, while larger sporadic tumors were diffusely, stronger stained for CgA and SPY. Therefore, stronger CgA and SPY immunostaining for larger tumors in both MEA2 and sporadic cases may be used as independent aggressive immunohistochemical markers for MTCs.
Identifiants
pubmed: 33485291
doi: 10.17305/bjbms.2020.5407
pmc: PMC8381211
doi:
Substances chimiques
CHGA protein, human
0
Chromogranin A
0
SYP protein, human
0
Synaptophysin
0
Calcitonin
9007-12-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-541Références
Pathol Annu. 1981;16(Pt 2):25-52
pubmed: 7036062
Nat Cell Biol. 2000 Jan;2(1):42-9
pubmed: 10620806
Cancer. 2006 Nov 1;107(9):2134-42
pubmed: 17019736
Medicine (Baltimore). 2014 Dec;93(27):e247
pubmed: 25501094
Cell. 1985 Sep;42(2):581-8
pubmed: 2992805
Differentiation. 1994 May;56(3):163-71
pubmed: 8034131
Bosn J Basic Med Sci. 2020 Aug 03;20(3):336-346
pubmed: 32020844
Indian J Cancer. 2019 Apr-Jun;56(2):173-175
pubmed: 31062739
Bioessays. 2004 Apr;26(4):445-53
pubmed: 15057942
J Clin Endocrinol Metab. 1959 Jan;19(1):152-61
pubmed: 13620740
Recent Results Cancer Res. 2015;204:61-90
pubmed: 26494384
Cancer Cytopathol. 2016 Dec;124(12):871-884
pubmed: 27529763
World J Methodol. 2017 Mar 26;7(1):9-15
pubmed: 28396845
Cancer Causes Control. 2009 Jul;20(5):525-31
pubmed: 19016336
Curr Genomics. 2011 Dec;12(8):618-25
pubmed: 22654561
Am J Surg Pathol. 1996 Feb;20(2):245-50
pubmed: 8554115
Virchows Arch. 1994;424(4):441-7
pubmed: 8205357
J Clin Endocrinol Metab. 2013 Aug;98(8):3149-64
pubmed: 23744408
Neuron. 2011 Jun 9;70(5):847-54
pubmed: 21658579
Proc Natl Acad Sci U S A. 1985 Jun;82(12):4137-41
pubmed: 3923488
Arch Med Sci. 2016 Feb 1;12(1):1-9
pubmed: 26925113
J Med Case Rep. 2013 Jan 21;7:26
pubmed: 23336429
Clin Endocrinol (Oxf). 2004 Sep;61(3):299-310
pubmed: 15355445
Eur J Cancer. 2012 Aug;48(12):1766-73
pubmed: 22133573
Thyroid. 2006 Nov;16(11):1163-70
pubmed: 17123344
Hum Mol Genet. 1994 Feb;3(2):237-41
pubmed: 7911697
JAMA. 2006 May 10;295(18):2164-7
pubmed: 16684987
Cancer. 1985 Oct 1;56(7):1649-57
pubmed: 2992743
Clin Gastroenterol Hepatol. 2008 Jul;6(7):820-7
pubmed: 18547872
J Clin Endocrinol Metab. 1997 Aug;82(8):2622-8
pubmed: 9253344
Thyroid. 2009 Jun;19(6):565-612
pubmed: 19469690
J Histochem Cytochem. 1986 Dec;34(12):1673-82
pubmed: 2878021
Histopathology. 1997 Aug;31(2):150-6
pubmed: 9279566
Endocr Pathol. 2000 Summer;11(2):165-172
pubmed: 12114822
Case Rep Endocrinol. 2019 Mar 12;2019:4038628
pubmed: 30993022
Neuron. 1999 Nov;24(3):687-700
pubmed: 10595519
Cell. 2006 Nov 17;127(4):831-46
pubmed: 17110340
Cancer. 2015 Jul 1;121(13):2137-46
pubmed: 25731779
N Engl J Med. 2003 Mar 20;348(12):1134-49
pubmed: 12646671
Endocr Pathol. 2005 Winter;16(4):279-83
pubmed: 16627915
Int J Biol Markers. 2004 Oct-Dec;19(4):295-304
pubmed: 15646836
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Curr Opin Oncol. 2007 Jan;19(1):18-23
pubmed: 17133107
Neurochem Res. 1993 Jan;18(1):59-64
pubmed: 8464536
J Med Case Rep. 2007 Nov 12;1:133
pubmed: 17997826
EMBO J. 2014 Apr 16;33(8):788-822
pubmed: 24596248
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32072159
Cancer. 2000 Mar 1;88(5):1139-48
pubmed: 10699905
Histopathology. 1994 Aug;25(2):183-5
pubmed: 7982684
Oncologist. 2008 May;13(5):539-47
pubmed: 18515739